OncoMatch/Clinical Trials/NCT05316935
GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients
Is NCT05316935 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2/3 trial studies multiple treatments including GnRHa and Letrozole 2.5mg for endometrial neoplasms.
Treatment: GnRHa · Letrozole 2.5mg · Diane-35 · MET — To investigate the efficacy of GnRHa plus letrozole vs Diane-35 plus metformin in non-obese progestin-insensitive early-stage endometrial cancer (EEC) and atypical hyperplasia(EAH) patients asking for conservative treatment.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Endometrial Cancer
Disease stage
Grade: g1
Demographics
Prior therapy
Must have received: progestin (megestrol acetate, medroxyprogesterone acetate, levonorgestrel intrauterine system (LNG-IUS)) — first-line
Using progestin, any of the following therapy, as first-line treatment: 1. Megestrol acetate ≥ 160 mg qd using, combined with Levonorgestrel Lntrauterine System (LNG-IUS) inserted or not 2. Medroxyprogesterone acetate ≥ 250 mg qd using, combined with LNG-IUS inserted or not 3. LNG-IUS inserted
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05316935 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received progestin.
Is there an age limit?
Yes. Patients must be 45 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages